Patients' Perspectives on the Definition of Cure in Chronic Myeloid Leukemia: A US Based Survey

Conclusion:This survey demonstrates that pts do not consider disease control with life-long oral medication as cure; rather, cure requires the absence of treatment. Overwhelmingly, pts indicated the importance of continuing CML research with an ultimate goal of treatment-free cure. The advent of oral TKIs has been a tremendous success for pts with this disease. Nevertheless, it remains a source of disruption in pts' lives, particularly through side effects and costs. The HJKC3 was initiated with the goal of curing CML.DisclosuresAtallah: Novartis: Consultancy; Jazz: Consultancy; Pfizer: Consultancy; BMS: Consultancy; Abbvie: Consultancy. Mauro: Bristol-Myers Squibb: Consultancy; Pfizer: Consultancy; Takeda: Consultancy; Novartis: Consultancy, Research Funding. Goldberg: COTA Inc.: Employment, Equity Ownership. Cortes: Daiichi Sankyo: Consultancy, Research Funding; Novartis: Consultancy, Research Funding; Pfizer: Consultancy, Research Funding; Astellas Pharma: Consultancy, Research Funding; Arog: Research Funding. Deininger: Pfizer: Consultancy, Membership on an entity's Board of Directors or advisory committees; Blueprint: Consultancy. Druker: ARIAD: Research Funding; Third Coast Therapeutics: Membership on an entity's Board of Directors or advisory committees; Patient True Talk: Consultancy; Amgen: Membership on an entity's Board of Directors or advisory committees; MolecularMD: Consultancy, Equity Ownership, Membership on an entity's Board of Directors or advisory committee...

Source: Blood - November 21, 2018 Category: Hematology Authors: George, G., Atallah, E. L., Mauro, M. J., Goldberg, S. L., Baim, A., Guhl, J., Hinman, A., Cortes, J. E., Deininger, M. W., Druker, B. J., Kota, V. K., Larson, R. A., Lipton, J. H., Moore, J. O., Oehler, V. G., Pinilla Ibarz, J., Radich, J., Ritchie, E. K Tags: 902. Health Services Research-Malignant Diseases Source Type: research